06:41 AM EDT, 10/24/2024 (MT Newswires) -- West Pharmaceutical Services ( WST ) reported Q3 adjusted earnings Thursday of $1.85 per diluted share, down from $2.16 a year earlier.

Analysts polled by Capital IQ expected $1.49.

Revenue for the quarter ended Sept. 30 was $746.9 million, compared with $747.4 million a year earlier.

Analysts surveyed by Capital IQ expected $709.6 million.

The company increased its 2024 adjusted EPS guidance to now be between $6.55 and $6.75 from the prior outlook of $6.35 to $6.65. Analysts polled by Capital IQ expect $6.41.

Net sales for the year are projected to be about $2.88 billion to about $2.91 billion, compared with a prior range of $2.87 billion to $2.90 billion. Analysts surveyed by Capital IQ expect $2.87 billion.

Price: 306.21, Change: +19.77, Percent Change: +6.90